Delivery Order SPE2DB20D3505-SPE2DB25FYCCF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 50 mg capsules (100 count units) with a ceiling value of $1,441.35. This is a firm fixed price delivery order with an ultimate completion date of September 2, 2025, and represents a non-competitive, non-set-aside award. The contract is performed from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $1,042.70. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 10 mg capsules (100-count units) under a firm fixed price contract on September 12, 2025, with a ceiling value of $1,337.70 and ultimate completion date of September 15, 2025. This non-competitive delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor for federal medical procurement, leveraging the company's existing indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Vyvanse 30 mg capsules (quantity 100) with a contract value of $1,163.08. This is a firm fixed price delivery order with an ultimate completion date of July 16, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Vyvanse 50 mg capsules in quantities of 100 units. This competitively awarded, firm fixed-price contract carries a ceiling value of $8,465.58 and is scheduled for completion by September 5, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Vyvanse 40 mg capsules (100 count) valued at $7,807.86 under a firm fixed-price contract. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $1,163.88. This non-set-aside delivery order is scheduled for completion by April 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger pharmaceutical...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FYCCFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Vyvanse 50 mg capsules (100 count) with a contract ceiling value of $4,076.22. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor agreement extending through December 2026 that provides comprehensive pharmaceutical support for military healthcare programs globally. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen supplies a broad portfolio of medications and medical products to defense and healthcare systems. This delivery order for Vyvanse, an attention-deficit hyperactivity disorder medication, represents a routine pharmaceutical procurement under the company's existing DLA framework. The award demonstrates AmerisourceBergen's continued capability to fulfill competitive federal medical supply requirements across multiple therapeutic domains in support of military and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.1k | 9/2/25 |